Similar articles

• Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.

  Sahai A, Khan MS, Dasgupta P. Sahai A, et al. J Urol. 2007 Jun;177(6):2231-6. doi: 10.1016/j.juro.2007.01.130. J Urol. 2007. PMID: 17509328 Clinical Trial.
• Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial.

  Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, Shah PJ, Malone-Lee J. Ghei M, et al. J Urol. 2005 Nov;174(5):1873-7; discussion 1877. doi: 10.1097/01.ju.0000177477.83991.88. J Urol. 2005. PMID: 16217327 Clinical Trial.
• Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.

  Sahai A, Dowson C, Khan MS, Dasgupta P. Sahai A, et al. BJU Int. 2009 Jun;103(11):1509-15. doi: 10.1111/j.1464-410X.2009.08402.x. Epub 2009 Apr 15. BJU Int. 2009. PMID: 19389019 Clinical Trial.
• Botulinum toxin in urinary incontinence.

  Patterson JM, Chapple CR. Patterson JM, et al. Curr Opin Urol. 2006 Jul;16(4):255-60. doi: 10.1097/01.mou.0000232046.87803.57. Curr Opin Urol. 2006. PMID: 16770124 Review.
• Botulinum toxin as a new therapy option for voiding disorders: current state of the art.

  Leippold T, Reitz A, Schurch B. Leippold T, et al. Eur Urol. 2003 Aug;44(2):165-74. doi: 10.1016/s0302-2838(03)00250-1. Eur Urol. 2003. PMID: 12875934 Review.